Teva and medincell announce positive phase 3 efficacy results from solaris trial evaluating tev-‘749 (olanzapine) as a once-monthly subcutaneous long-acting injectable in adults with schizophrenia

Parsippany, n.j. & tel aviv, israel & paris--(business wire)--teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), and medincell (euronext: medcl), today announced results from the efficacy portion of the phase 3 subcutaneous olanzapine extended-release injection study (solaris) trial evaluating tev-‘749 in adult patients with schizophrenia compared to placebo. results demonstrated that tev-‘749 met its primary endpoint as measured by a change in.
TEVA Ratings Summary
TEVA Quant Ranking